ABSTRACT
Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillin-tazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer's instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillin-tazobactam concentrations in the serum. Results were all negative for galactomannan detection, even at high drug concentrations. Results from this pilot study suggest that piperacillin-tazobactam might not be a clinically significant cause of false-positive results in the Platelia Aspergillus EIA test in Brazil.
Subject(s)
Anti-Bacterial Agents/chemistry , Aspergillus/immunology , Immunoenzyme Techniques , Mannans/analysis , False Positive Reactions , Penicillanic Acid/analogs & derivatives , Penicillanic Acid/chemistry , Piperacillin/chemistryABSTRACT
Mostra a biodisponibilidade, a farmacinética, a atividade in vitro, os estudos clínicos, a segurança, os efeitos colaterias, a posologia e a relação custo/benfício da junção da pipericilina sódica com a tazobactama sódica